Natalia A. Tomilina

Natalia A. Tomilina

Auto-generated profile, based on publicly available information

Natalia A. Tomilina

M.F. Vladimirsky Moscow Regional Clinical Research Institute; V.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and Gynecology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MZM L Zubkin
M L Zubkin
NFN F Frolova
N F Frolova
IKI G Kim
I G Kim
AUA I Ushakova
A I Ushakova
SUS S Usatiuk
S S Usatiuk
EKE V Kryukov
E V Kryukov
Background. Present concepts of the novel coronavirus infection prognosis in haemodialysis (HD) patients are rather controversial. There is little information on therapy efficiency and safety in such patients. We studied COVID-19 course specifics, prognostic factors associated with fatal outcomes, therapy efficiency and its transformation at different stages of the pandemic first year. Materials and methods. Single-centre retrospective uncontrolled study included 653 COVID-19 HD-patients treated at Moscow City Nephrology Centre from April 1 to December 31, 2020. Results. This period mortality rate was 21.0%. Independent predictors of COVID-19 unfavourable outcome in HD patients were pulmonary lesion extension (CT grades 34), high comorbidity index, and mechanical ventilation. Approaches to COVID-19 treatment modified significantly at different periods. Immunomodulatory drugs (monoclonal antibodies to IL-6, corticosteroids) were used largely at later stages. With tocilizumab administration, mortality was 15.1%, tocilizumab together with dexamethasone 13.3%; without them 37.8% (р0,001). Tocilizumab administration in the first 3 days after hospitalization of patients with CT grades 12 was associated with more favourable outcomes: 1 out of 29 died vs 6 out of 20 (tocilizumab administered at later periods); p0.04. There was no significant difference in death frequency in patients with CT grades 34 depending on tocilizumab administration time. Conclusion. COVID-19 in HD patients can manifest in a severe course with unfavourable outcome. It is urgent to identify reliable disease outcome predictors and develop efficient treatment in this population.

15 December 2016 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ASA. G. Stolyar
A. G. Stolyar
NTN A Tomilina
N A Tomilina
Aim. To investigate the impact of smoking on kidney transplantation outcomes. Subjects and methods. The materials of 350 patients (including 229 (65.4%) men aged 37.1±0.6 years) who had undergone kidney allotransplantation (KAT) for end-stage renal disease were analyzed. The main outcomes of KAT (patient status (alive or dead); renal allograft (RAG) function or dysfunction; development of chronic transplant nephropathy (CTN)), were studied. Results. There were 52 (14.8%) smoking patients (50 (96.2%) men and 2 (3.8%) women). The survival rate of smokers after KAT was significantly lower (p=0.043), as was the duration of graft function in the smoking patients (p=0.038). There were statistically significant associations of smoking with age, sex, time to normalize post-KAT serum creatinine concentrations, the development of CTN and graft rejection crises, postoperative hypertension, post-KAT serum creatinine, hemoglobin, and albumin levels, pretransplantation alanine aminotransferase concentrations, pre-KAT left ventricular hypertrophy, patient compliance with the prescribed treatment regimen, the presence or absence of a job in the patient after KAT (p

1 January 2020 in Nephrology and Dialysis
Verified
Journal Article
Closed access
M5Moscow City Hospital 52
Moscow City Hospital 52
EIE.S. Ivanova
E.S. Ivanova
ESE.S. Stolyarevich
E.S. Stolyarevich
MOMoscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry; V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Moscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry; V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs
OEO.Y. Evsyukov
O.Y. Evsyukov
MDMoscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Moscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry

22 March 2025 in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
EPE. I. Prokopenko
E. I. Prokopenko
FBF. F. Burumkulova
F. F. Burumkulova
TKT. S. Kovalenko
T. S. Kovalenko
AVA. V. Vatazin
A. V. Vatazin
The prevalence of type 2 diabetes mellitus (DM2) and obesity in pregnant women is increasing, particularly in those of advanced reproductive age. DM2, arterial hypertension (AH), proteinuria, and renal insufficiency significantly elevate the risk of pregnancy complications, including preeclampsia (PE), preterm birth, cesarean section (CS), congenital malformations, neonatal respiratory and metabolic disorders, and accelerated progression of chronic kidney disease in mothers. This article describes a case of unplanned pregnancy in a 45-year-old woman with morbid obesity (BMI 50.39), AH, DM2, extremely high proteinuria (12 g/day), and pregestational serum creatinine 210 μmol/L. The patient declined medical recommendations for pregnancy termination. She was prescribed insulin detemir and aspart, achieving a target HbA1C level below 6%. Acetylsalicylic acid and enoxaparin were administrated to prevent PE and thromboembolic complications. Antihypertensive therapy was adjusted multiple times based on 24-h blood pressure monitoring. By 26 weeks of gestation, the patient received methyldopa, extended-release nifedipine, and bisoprolol. No PE or fetal growth restrictions was observed. At 36 weeks 4 days of gestation, a planned CS was performed due to breech presentation. A female infant with diabetic fetopathy was delivered with weight 3290 g, height 51 cm, Apgar score – 7/8 points. The postpartum period was uneventful, and both mother and child were discharged at eighth day. The infant remains healthy and is developing normally. The mother was resumed nephroprotective therapy but, by her own decision, was lost to follow-up after six months. It is known she began regular hemodialysis 1.5 years postpartum. A favorable obstetric outcome was achieved through multidisciplinary pregnancy management, complication prevention, and strict glycemic and blood pressure control.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Open access
NFN.F. Frolova
N.F. Frolova
MDMoscow City Hospital 52 of Moscow Health Department
Moscow City Hospital 52 of Moscow Health Department
NTN.A. Tomilina
N.A. Tomilina
SUS.S. Usatiuk
S.S. Usatiuk
LAL.Yu. Artyukhina
L.Yu. Artyukhina
GMG.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology
Моноклональные антитела к рецептору интерлейкина-6 при лечении COVID-19 у пациентов с хронической болезнью почек

26 December 2025 in Nephrology and Dialysis
Verified
Journal Article
Closed access
EIE. S. Ivanova
E. S. Ivanova
NTN. A. Tomilina
N. A. Tomilina
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
OKO. N. Kotenko
O. N. Kotenko
NFN. F. Frolova
N. F. Frolova
LAL. Yu. Artyukhina
L. Yu. Artyukhina
The aim of this retrospective study was to comparatively analyze the clinical course and outcomes of aHUS with genetic complement abnormalities using both our own data and published literature. Materials and methods . This retrospective study included 55 patients with aHUS (mean age 36.4±8.9 years, 56% male, 44% female) treated between January 2014 and August 2024 at the Moscow Scientific and Practical Center of Nephrology and Pathology of Transplanted Kidney of Moscow City Hospital No 52. Results . Genetic abnormalities were identified in 61% of patients with aHUS. The most frequently detected variants were CFHR3/CFHR1 (29%), C3 (20%) and CFH (15%). Patients with and without genetic mutations did not differ significantly in sex, age, presence of the full TMA triad, malignant arterial hypertension (MAH), or extrarenal manifestations (р>0.05). Cardiac involvement was more common in patients with CFH variants (24%), and intestinal involvement was more frequent in patients with CFHR3/CFHR1 (56%); however these differences did not reach statistical significance ( р >0.05). Five-year renal survival did not differ significantly between patients with or without genetic mutations (50% vs. 65%, respectively, р =0.413), or depending on the presence of MAH (38% vs. 64%, р =0.08) or extrarenal manifestations (43% vs. 64%, р =0.17). All patients with CFH mutation experienced loss of renal function within 5 years despite treatment with eculizumab. A significant improvement in renal survival was observed only in patients who initiated eculizumab therapy within first month of disease onset, compared with those who started treatment after a month or later (89% vs. 11%, respectively, р =0.0001). The five-year mortality rate among patients with aHUS was 7%. Mortality did not differ significantly based on the presence of genetic abnormalities (0% vs. 16%, р =0.295), MAH (33% and 6%, р >0.5) or extrarenal manifestations (14% vs. 0%, р =0.451). Conclusions . Demographic and clinical characteristics did not differ significantly between patients with or without complement-related genetic abnormalities. A pronounced decrease in renal survival was observed found in patients with CFH mutations compared with whose carrying CFHR1/CFHR3 or without genetic mutations. Five-year renal survival and mortality rate were not significantly associated with other genetic variants, MAH, or extrarenal involvement. Early initiation of eculizumab therapy – within the first month after disease onset – markedly improved renal outcomes and reduces mortality.